Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Kyorin: Sales Up 5.2% Driven by Good Sales of Kipres
June 2, 2008
- Protosera Cooperates with 5 Firms to Search for Biomarkers
June 2, 2008
- SELF-MEDICATION NEWS IN BRIEF
June 2, 2008
- Kaken: Artz Drives 4.6% Increase in Sales
June 2, 2008
- MEDICAL DEVICE NEWS IN BRIEF
June 2, 2008
- JPMA Predicts \1.7 Tril. Shrinkage of Market under NHI Pricing System Proposed by It
June 2, 2008
- Mochida: Record-high Profits Driven by Epadel, Atelec
June 2, 2008
- JSMI Calls on Original Makers to Cooperate in Development of Switch OTC Drugs
June 2, 2008
- Industry's NHI Pricing System Reform Proposal Needs Careful Review: Chuikyo Chairman
June 2, 2008
- Kissei: Drop in Sales of Cabaser Hits Business
June 2, 2008
- TOPICS／SSRI Package Inserts Require Revision: Medwatcher Japan↓
June 2, 2008
- Industry Must Justify Its Pricing System Reform Proposal with Data: Mr Isobe
June 2, 2008
- Nippon Shinyaku: Hypen Drives Sales, Profits
June 2, 2008
- Exclusion of OTC-Like Drugs from Insurance Coverage May Become Issue Again: Mr Isobe
June 2, 2008
- Zeria: Sales Down 5.8% due to Disappointing Sales of Ethical Drugs
June 2, 2008
- REGULATORY NEWS IN BRIEF
June 2, 2008
- Torii: Anti-HIV Drugs Drive Sales
June 2, 2008
- E7389 Shows Anti-tumor Activity for Advanced Breast Cancer: Eisai
June 2, 2008
- ASKA: Competition Cuts Sales, Profits
June 2, 2008
- R&D NEWS IN BRIEF
June 2, 2008
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…